EXELIXIS der nächste Durchstarter ????? - 500 Beiträge pro Seite

[JS222]

Top NEWS

Exelixis Announces Broad Alliance with GlaxoSmithKline to Discover and Develop Novel Therapeutics
via COMTEX

October 28, 2002

SAN FRANCISCO, Oct 28, 2002 (BUSINESS WIRE) --

Exelixis, Inc. (Nasdaq: EXEL) today announced the establishment of a broad alliance with GlaxoSmithKline to discover and develop novel therapeutics. Exelixis will host a conference call at 5:00 pm ET to discuss this new alliance. The call will be led by George A. Scangos, Ph.D., president and chief executive officer, with other senior management participating.

The call will be webcast on the investor relations section of Exelixis`website at www.exelixis.com/ir (click on the Corporate Collaboration icon) and at www.ccbn.com and will be archived until November 11, 2002.

Exelixis, Inc. (Nasdaq: EXEL) is a leading genomics-based drug discovery company focused on product development through its expertise in comparative genomics and model system genetics. These technologies provide a rapid, efficient and cost effective way to move from DNA sequence data to knowledge about the function of genes and the proteins they encode. The company`s technology is broadly applicable to all life sciences industries including pharmaceutical, diagnostic, agricultural biotechnology and animal health. Exelixis has partnerships with Bayer CropScience, Bristol-Myers Squibb, Cytokinetics, Dow Agrosciences, Elan Pharmaceuticals, Merck, Protein Design Labs, Schering-Plough Research Institute and Scios and is building its internal development program in the area of oncology. For more information, please visit the company`s web site at www.exelixis.com.Exelixis and the Exelixis logo are registered U.S. trademarks.

Exelixis, Inc. Jane M. Green, 650/837-7579 [e-mail]

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.

Copyright (C) 2002 Business Wire. All rights reserved.

JS200

[JS222]

10/28/2002 (16:10 ET) New 8-K just released for EXEL - Edgar
10/28/2002 (16:00 ET) Exelixis Announces Broad Alliance with GlaxoSmithKline to Discover and Develop Novel Therapeutics - Business Wire
10/28/2002 (16:00 ET) Exelixis and GlaxoSmithKline Form Broad Alliance To Discover and Develop Novel Therapeutics - PR Newswire
10/24/2002 (16:16 ET) Exelixis Announces Third Quarter 2002 Financial Results Conference Call and Webcast - Business Wire
10/08/2002 (16:17 ET) 52W LOW: New 52-Wk Low for EXEL @ $2.950 dn4.19% - Knobias

JS200

[JS222]

Von GESTERN

EXEL
ELELIXIX INC
3.580
+0.180 +5.29%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/14/2002 (14) days ago, when the stock price was 3.355. Since then the stock gained 6.71% .

Today the stock closed higher with a higher high and a higher low. The volume is low. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
White Candlestick

Today a White Candlestick formed. Buyers were in control but the buying pressure was not very strong.

Stock Quote
Last 3.580
Previous Close 3.400
Change +0.180
% Change +5.29%
Volume 173,490
Stock Activity
Open 3.480
Day`s High 3.660
Day`s Low 3.460
52 Week High 17.110
52 Week Low 3.020

Stock Price History
3 Month % Change -30.62
6 Month % Change -61.67
12 Month % Change -72.14
Stock Statistics
50 Day Close MA 4.193
200 Day Close MA 7.947
65 Day Volume MA 302,512

JS200

[JS222]

company news

--------------------------------------------------------------------------------

EXEL - Exelixis Incorporated (NASDAQ NM : EXEL)

--------------------------------------------------------------------------------
GlaxoSmithKline in development alliance with Exelixis; pays 30 mln usd upfront



TUESDAY , OCTOBER 29, 2002 02:39 AM

LONDON, Oct 29, 2002 (AFX-Europe via COMTEX) -- GlaxoSmithKline PLC said it has entered a broad alliance with Exelixis Inc to discover and develop novel therapeutics in the areas of vascular biology, inflammatory disease and oncology.

Under the terms of the agreement, Exelixis will have responsibility for the delivery to GSK of an undisclosed number of small-molecule compounds that have met agreed-upon criteria in early Phase II clinical testing. GSK will have the right to further develop these compounds and exclusive, worldwide commercialization and manufacturing rights. Exelixis retains co-promotion rights in North America.

GSK said it will make an upfront payment of 30 mln usd to Exelixis. GSK will also initially acquire two million newly issued shares of Exelixis common stock at 7 usd per share, which represents a premium of approximately 100 pct to the current stock price. Exelixis has the option to sell GSK additional shares at a specified time in the future.

Over the initial six years of the agreement, GSK said it will provide Exelixis with a minimum of 90 mln usd in development funding. Exelixis will receive clinical and regulatory milestone payments based on progress in the number and timing of compounds. Based on the continued successful development of these compounds, these payments could range from 220 mln to 350 mln usd up to and including first commercialization, said GSK.

In addition, GSK said it will make available a loan facility to Exelixis of up to 85 mln usd.

Exelixis will also receive sales-based milestone payments and royalties on product sales.

Two years from the start of the collaboration, GSK and Exelixis may elect to expand the collaboration, and under this option, Exelixis` milestone payments could double in size, and the development funding and the loan facility would also be "significantly expanded", said GSK.

[e-mail]

slm/



Copyright 2002. AFX News Ltd. All rights reserved.


-0-


KEYWORD: United Kingdom
INDUSTRY KEYWORD: Health Care
SUBJECT CODE: Joint Ventures
Production or Sales


STOCK SYMBOLS: [(gsk)]


JS200

[JS222]

GLAXO bezahlt 100% Aufschlag, schneller kann keine Aktie fliegen

JS200

[JS222]

10/29/2002 (02:39 ET) GlaxoSmithKline in development alliance with Exelixis; pays 30 mln usd upfront - AFX News UK
10/29/2002 (02:39 ET) GlaxoSmithKline in development alliance with Exelixis; pays 30 mln usd upfront - AFX News Europe
10/28/2002 (16:10 ET) New 8-K just released for EXEL - Edgar
10/28/2002 (16:00 ET) Exelixis Announces Broad Alliance with GlaxoSmithKline to Discover and Develop Novel Therapeutics - Business Wire
10/28/2002 (16:00 ET) Exelixis and GlaxoSmithKline Form Broad Alliance To Discover and Develop Novel Therapeutics - PR Newswire


JS200

[JS222]

company news

--------------------------------------------------------------------------------

EXEL - Exelixis Incorporated (NASDAQ NM : EXEL)

--------------------------------------------------------------------------------
GAP-UP: Opening Higher EXEL EQIX EDSN ADVP LUME



TUESDAY , OCTOBER 29, 2002 09:40 AM

In the first half hour of trading, these five stocks opened significantly higher than their previous close and are temporarily sustaining those gains.

Open +53.63% *** Exelixis Incorporated (NasdaqNM: EXEL)
--------------------[Announced that they will form a broad alliance to discover, develop and commercialize novel therapeutics in the areas of vascular biology, inflammatory disease and oncology]

Open +22.69% *** Equinix Inc (NasdaqNM: EQIX)
--------------------[Announced an agreement with Japan Telecom and the launch of its Equinix GigE Exchange(TM) service to customers of the company`s Los Angeles area Internet Business Exchange(TM) (IBX(R)) center]

Open +13.64% *** Edison Schools Incorporated (NasdaqNM: EDSN)
--------------------[10/28: The Philadelphia school system sent Edison Schools its first $5.3 million paycheck this week after signing a deal guaranteeing that the district wouldn`t be left without school equipment and supplies if the company failed]

Open +13.54% *** AdvancePCS,Incorporated (NasdaqNM: ADVP)
--------------------[Announced Revenues and Earnings results for the second quarter ended Sept. 30, 2002; Raised guidance for Fiscal 2003; three analyst upgrades today]

Open +13.27% *** Lumenis Ltd (NasdaqNM: LUME)
--------------------[Announced that it received marketing clearance from the U.S. Food & Drug Administration for the new ReLume Repigmentation Phototherapy System for the treatment of leukoderma, or the loss of skin pigmentation]

Each morning between 9:30 ET and 10:00 ET, Knobias will report on selected over-the-counter stocks that have “gapped-up” in early trading. Each of these alerts will contain a maximum of five OTC stocks during the first 30 minutes of trading.

JS200

[JS222]

company news

--------------------------------------------------------------------------------

EXEL - Exelixis Incorporated (NASDAQ NM : EXEL)

--------------------------------------------------------------------------------
VOLUME(+): EXEL Volume 99% > 20-adsv, Stock +50.28%



TUESDAY , OCTOBER 29, 2002 09:52 AM

This is the 1st VOLUME alert for EXEL in the past 7 calendar days.

Trading for Exelixis Incorporated (NASDAQ NM: EXEL) has been heavier than usual in today`s session. By 09:50 ET, the stock had already traded 616,200 shares via 364 trades. The cumulative volume is 99.41% above than its 20-day average of 309,011. Normally the stock experiences around 431 individual trades per session.

So far, today`s volume surge has caused a net rise in EXEL`s stock price. At the time of this alert, the stock was trading at $5.380, up $1.800 (+50.28%).

One year ago, the Company`s shares closed at $12.700. The price has declined more than 57 percent since then.

Over the last 10 trading session EXEL has traded in a range between $3.350 and $4.450 and is currently trading 69.20% below its 52-week high of $17.470 set on December 18, 2001 and 82.37% above its 52-week low of $2.950 from October 09, 2002.

In the previous 3 sessions, EXEL trading has displayed a mixed trend. Closing results have been as follows:

October 28, 2002 --- closed at $3.580 up $0.180 (+5.29%) on 233,500 shares
October 25, 2002 --- closed at $3.400 down $0.150 (-4.23%) on 263,000 shares
October 24, 2002 --- closed at $3.550 down $0.349 (-8.95%) on 300,400 shares

The Company last released news on October 28, 2002 (yesterday):

"Exelixis Announces Broad Alliance with GlaxoSmithKline to Discover and Develop Novel Therapeutics"

EXELIXIS INCORPORATED
Exelixis, Inc. is a biotechnology company whose primary mission is to develop proprietary human therapeutics by leveraging it`s integrated discovery platform to increase the speed, efficiency and quality of pharmaceutical product discovery and development. The Company uses comparative genomics and model system genetics to find new drug targets that it believes would be difficult or impossible to uncover using other experimental approaches. The Company`s research is designed to identify novel genes and proteins expressed by those genes that, when changed, either decrease or increase the activity in a specific disease pathway in a therapeutically relevant manner. These genes and proteins represent either potential product targets or drugs that may treat disease or prevent disease initiation or progression. The Company`s most advanced proprietary pharmaceutical program focuses on drug discovery and development of small molecules in cancer.


JS200

[JS222]

EXELIXIS INC - Nasdaq National Market: EXEL

Consolidated Real-time Market Quote*
Last Change (%) After Hours Chg (%)** Bid Ask Trade Time
5.03 1.45 (40.50) 0.03 (0.60) 5.07 (10) 5.20 (10) 15:58

--------------------------------------------------------------------------------
Exchange QuoteLast Change (%) Bid (size) Ask (size) Trade Time
5 1.42 (39.66) 5.02 (1) 5.07 (1) 15:50
Day Volume Last Size Open High Low
3,707,800 500 5.90 5.90 4.85
Latest Ticks # of Trades Avg Trade Size 52 Wk High 52 Wk Low
-+-- 4,597 807 N/A 2.9531
Prev Close VWAP Avg Day Vol
3.58 5.2891 290,000

JS200

[JS222]

VON GESTERN

EXEL
ELELIXIX INC
5.060
+1.480 +41.34%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/14/2002 (15) days ago, when the stock price was 3.355. Since then the stock gained 50.82% .

Today the stock closed higher, close to its low (sign of weakness) with a higher high and a higher low. A bullish gap occured, which may indicate an upward break out.The volume is extremely high. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Long Black Candlestick

Today a Long Black Candlestick formed. Sellers were aggressive and selling pressure was strong. Be careful, this may be a potential turning point!

Stock Quote
Last 5.060
Previous Close 3.580
Change +1.480
% Change +41.34%
Volume 3,922,058
Stock Activity
Open 5.900
Day`s High 5.900
Day`s Low 4.850
52 Week High 17.110
52 Week Low 3.020

Stock Price History
3 Month % Change -1.94
6 Month % Change -45.82
12 Month % Change -60.62
Stock Statistics
50 Day Close MA 4.195
200 Day Close MA 7.899
65 Day Volume MA 358,480

JS200

[JS222]

Von GESTERN

EXEL
ELELIXIX INC
4.940
-0.100 -1.98%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 10/14/2002 (17) days ago, when the stock price was 3.355. Since then the stock gained 47.24% .

Today the stock closed lower, close to its low (sign of weakness) with a lower high and a higher low (sign of decrease in volatility). The volume is normal. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Short Black Candlestick

Today a Short Black Candlestick formed. There was a limited price change that may represent consolidation

Stock Quote
Last 4.940
Previous Close 5.040
Change -0.100
% Change -1.98%
Volume 402,929
Stock Activity
Open 5.040
Day`s High 5.140
Day`s Low 4.900
52 Week High 17.110
52 Week Low 3.020

Stock Price History
3 Month % Change -29.33
6 Month % Change -50.10
12 Month % Change -63.13
Stock Statistics
50 Day Close MA 4.199
200 Day Close MA 7.809
65 Day Volume MA 351,218

JS200

[js200]

11/29/2002 (13:21 ET) VOLUME(+): EXEL Volume 48% > 20-adsv, Stock +11.85% - Knobias
11/25/2002 (15:47 ET) New 4 just released for EXEL - Edgar
11/22/2002 (15:10 ET) Form 4: Exelixis Director Formela Sells 70K Shares - Knobias
11/22/2002 (15:05 ET) New 4 just released for EXEL - Edgar

JS200

[js200]

Freitag, nicht schlecht gelaufen
Last Trade: 9.060 Change: 0.960 (+11.852%)
Previous Close: 8.100 Volume: 909,500
Bid: 8.080 Ask: 8.130
Today`s Open: 8.130 # of Trades: 1,166


JS200

[js200]

Gewinne scheinen mirgenommen zu sein

Auf bessere Zeiten

JS200

[js200]

Agrinomics and Renessen Establish Alliance to Enhance Seed Oil Content
via COMTEX

December 19, 2002

SOUTH SAN FRANCISCO, Calif. and MONHEIM, Germany, Dec 19, 2002 /PRNewswire-FirstCall via COMTEX/ --

Exelixis, Inc. (Nasdaq: EXEL) and Bayer CropScience AG announced that Agrinomics LLC, a joint venture between Exelixis Plant Sciences (EPS) and Bayer CropScience LP, and Renessen LLC, a joint venture between Monsanto Company and Cargill, Inc., have established a collaboration to enhance the oil content in commercially valuable seed oil crops. The collaboration combines Agrinomics`technological leadership in agricultural functional genomics, high-throughput gene screening and seed trait identification, developed at Exelixis Plant Sciences, with Renessen`s global expertise in quality trait crop development and commercialization, with the goal of accelerating the development of novel proprietary crops with improved seed composition traits.

This innovative collaboration will explore new ways to use insights gained from agricultural functional genomics to enhance plants`genetic capabilities to increase the value of the natural compounds they produce. The global market for seed oil production is estimated to be $32 billion, and is growing at the rate of 3% per year, as major agricultural producers compete to produce human and animal food products that are more nutritionally beneficial, environmentally safe and commercially valuable. Two oil seed crops, soybeans and canola, account for over 70% of the 336 million metric ton world oil seed production capacity, and 44% of the 92 million metric ton world vegetable oil consumption market. Soy oil alone represents an annual market of more than $16 billion.

Under the terms of the collaboration, Renessen will provide Agrinomics with committed annual research funding, payment for the selection of genes and other product options, pre-commercial milestones as crop products advance through field testing and regulatory approval, and royalties on commercialized products that may emerge from the collaboration. In addition, Renessen will contribute research and product development capabilities in taking gene candidates identified by Agrinomics into crop products that include leading commercial germplasm. Specific financial terms of the collaboration are not being released.

`Our collaboration with Renessen underscores the unique capabilities of Agrinomics`powerful ACTTAG(TM) trait selection platform to rapidly discover and validate genes that can optimize important seed traits and increase the commercial value of many of the world`s most significant agricultural crops,` said Glen Y. Sato, Exelixis`chief financial officer, vice president, legal affairs, and chief executive officer, Agrinomics. `We believe that this significant partnership will advance the goal of creating a highly productive independent plant trait discovery business.`

`We believe that Agrinomics`novel ACTTAG(TM) gene activation and tagging technology, coupled with its creative high throughput screening platform for seed composition traits, provides a strong complement to the internal research and development strategies of Renessen and its parent companies. Furthermore, this partnership should provide a significant competitive advantage in the race to create more commercially attractive high oil content crops,`said Doug Hard, Renessen VP, Regulatory Affairs and Public Acceptance. `We believe that by harnessing innovative new research technologies to improve crop traits to our strengths in biotechnology development, crop breeding and production, Renessen has the potential to increase its leadership in major areas of the agricultural value chain.`

Agrinomics has developed a robust gene discovery platform using the model plant species Arabidopsis thaliana, a plant related to commercial canola. This platform uses a proprietary positive genetic trait identification methodology known as `activation tagging`or ACTTAG(TM). Agrinomics has created a fully indexed and archived collection of over 250,000 ACTTAG(TM) Arabidopsis lines that represent nearly complete coverage of the entire Arabidopsis genome. To date, a large number ACTTAG(TM) lines have been identified that have improved seed oil and seed protein content, or have enhance seed oil or protein composition.

Renessen LLC develops and delivers quality traits and customized products that enhance the functionality of grains, oilseeds and other crops for grain processing and animal feed. Renessen is a joint venture between two global leaders: Monsanto Company and Cargill, Incorporated. As the first global alliance to span the value chain, Renessen has the research and technology to create high value products and the processing and distribution expertise to deliver these products.

Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics, with a focus in the area of oncology. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, and Protein Design Labs. The company has also established agricultural research collaborations with Bayer CropScience, Dow Agrosciences and Renessen LLC. Other partners include Merck, Schering-Plough Research Institute, Cytokinetics and Scios. For more information, please visit the company`s web site at www.exelixis.com.

Bayer CropScience AG, a subsidiary of Bayer AG with current annual sales of some EUR 6.0 billion, is one of the world`s leading innovative crop science companies in the areas of crop protection, seeds and green biotechnology, as well as non-agricultural pest control. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of 22,000 and is represented in 122 countries, ensuring proximity to dealers and consumers.

The forward looking statements contained in this press release involve risks and uncertainties that may affect our research and development efforts, as more fully discussed in the `Risk Factors`section of our filings with the U.S. Securities and Exchange Commission. These risks and uncertainties include, but are not limited to, the ability of Exelixis to identify and deliver high oil genes in order to achieve the goals of the collaboration, milestones and royalty payments; and the ability of Renessen to successfully develop and market crops with increased oil content.

NOTE: Exelixis and the Exelixis logo are registered U.S. trademarks. MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X32564794

SOURCE Exelixis, Inc.

Jane M. Green, Ph.D., VP, Corporate Communications of Exelixis, Inc., [phone], or [e-mail]; or Norbert Lemken, Corporate Communications of Bayer CropScience AG, [phone], or [e-mail]

http://www.exelixis.com


JS200

[JS222]

12/31/2002 (16:16 ET) VOLUME(+): EXEL Volume 143% > 20-adsv, Stock +12.71% - Knobias
12/19/2002 (09:49 ET) RATING(=): Pacific Growth Reiterations, 12/19/02 - Knobias
12/19/2002 (06:00 ET) Agrinomics and Renessen Establish Alliance to Enhance Seed Oil Content - PR Newswire
12/17/2002 (08:54 ET) Research and Markets Ltd: The 100 Major Manufacturing Firms -- Biotechnology - Research - M2 Communications
12/13/2002 (11:20 ET) New 4 just released for EXEL - Edgar


JS200

[JS222]

company news

--------------------------------------------------------------------------------

EXEL - Exelixis Incorporated (NASDAQ NM : EXEL)

--------------------------------------------------------------------------------
RATING(=): Pacific Growth Reiterations, 12/19/02



THURSDAY , DECEMBER 19, 2002 09:49 AM

According to Briefing.com, Pacific Growth Equities keeps its rating for the following:

- Versicor Inc (NasdaqNM: VERS) @ OVERWEIGHT

- Pharmacyclics, Inc. (NasdaqNM: PCYC) @ EQUAL-WEIGHT

- Exelixis Inc (NasdaqNM: EXEL) @ OVERWEIGHT

- BEA Systems, Inc. (NasdaqNM: BEAS) @ EQUAL-WEIGHT

JS200

[JS222]

company news

--------------------------------------------------------------------------------

EXEL - Exelixis Incorporated (NASDAQ NM : EXEL)

--------------------------------------------------------------------------------
VOLUME(+): EXEL Volume 143% > 20-adsv, Stock +12.71%



TUESDAY , DECEMBER 31, 2002 04:16 PM

This is the 1st VOLUME alert for EXEL in the past 7 calendar days.

Trading for Exelixis Incorporated (NASDAQ NM: EXEL) has been heavier than usual in today`s session. By 16:15 ET, the stock had already traded 543,300 shares via 1,258 trades. The cumulative volume is 142.64% above than its 20-day average of 223,912. Normally the stock experiences around 534 individual trades per session.

So far, today`s volume surge has caused a net rise in EXEL`s stock price. At the time of this alert, the stock was trading at $7.980, up $0.900 (+12.71%).

Eleven months ago, the Company`s shares closed at $15.810. The price has declined more than 49 percent since then.

Over the last 10 trading session EXEL has traded in a range between $6.830 and $8.310 and is currently trading 52.27% below its 52-week high of $16.720 set on January 09, 2002 and 170.51% above its 52-week low of $2.950 from October 09, 2002.

In the previous 3 sessions, EXEL trading has displayed a negative trend. Closing results have been as follows:

December 30, 2002 --- closed at $7.080 down $0.020 (-0.28%) on 146,000 shares
December 27, 2002 --- closed at $7.100 down $0.210 (-2.87%) on 143,400 shares
December 26, 2002 --- closed at $7.310 down $0.252 (-3.33%) on 177,200 shares

The Company last released news on December 19, 2002:

"Agrinomics and Renessen Establish Alliance to Enhance Seed Oil Content"

EXELIXIS INCORPORATED
Exelixis, Inc. is a biotechnology company whose primary mission is to develop proprietary human therapeutics by leveraging it`s integrated discovery platform to increase the speed, efficiency and quality of pharmaceutical product discovery and development. The Company uses comparative genomics and model system genetics to find new drug targets that it believes would be difficult or impossible to uncover using other experimental approaches. The Company`s research is designed to identify novel genes and proteins expressed by those genes that, when changed, either decrease or increase the activity in a specific disease pathway in a therapeutically relevant manner. These genes and proteins represent either potential product targets or drugs that may treat disease or prevent disease initiation or progression. The Company`s most advanced proprietary pharmaceutical program focuses on drug discovery and development of small molecules in cancer.


JS200

[JS222]

Vom 31ten Dezember

EXEL
ELELIXIX INC
8.000
+0.920 +12.99%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 12/18/2002 (13) days ago, when the stock price was 7.830. Since then the stock gained 2.17% .

Today the stock closed higher, close to its high (sign of strength) with a higher high and a higher low. The volume is high. The security price is trending down.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and the buying pressure was strong. Be careful, this may be a potential turning point!

Stock Quote
Last 8.000
Previous Close 7.080
Change +0.920
% Change +12.99%
Volume 633,255
Stock Activity
Open 6.980
Day`s High 8.110
Day`s Low 6.900
52 Week High 16.620
52 Week Low 3.020

Stock Price History
3 Month % Change 61.62
6 Month % Change 17.47
12 Month % Change -51.87
Stock Statistics
50 Day Close MA 6.776
200 Day Close MA 6.855
65 Day Volume MA 376,056

JS200

[js200]

Research and Markets: Biotechnology - Research Value Set
via COMTEX

January 6, 2003

Jan 06, 2003 (M2 PRESSWIRE via COMTEX) --

Get both an Industry Report and 100 full profiles on major manufacturing firms in the Biotechnology - Research industry. The Value Set combines the Industry Report and the 100 Major Firm Profiles collection at a better value than buying them separately. Receive both a unique perspective on your target industry as well as detailed profile information on 100 major manufacturing companies in the industry.

Companies within this SIC/NAICS code: 3-Dimensional Pharmaceuticals, Inc., Affymetrix, Inc., Alizyme Therapeutics Ltd., Amersham Biosciences, Applera Corporation, Applied Biosystems Group, Applied Molecular Evolution, Inc., Argonaut Technologies, Inc., Array BioPharma Inc., Asclepion-Meditec AG, Athersys, Inc., Aurora Biosciences Corporation, Axonyx Inc., Biacore International AB, Biosample.com, Inc., BioSource International, Inc., BioSphere Medical, Inc., Brock Rogers Surgical Inc., Caliper Technologies Corp., Cellomics, Inc., Celsion Corporation, Cepheid, Ciphergen Biosystems, Inc., CombiMatrix Corporation, Compugen Ltd., Crucell N.V., CuraGen Corporation, Cyrano Sciences, Inc., deCODE genetics, Inc., Deltagen, Inc., diaDexus, Inc., Discovery Partners International, Inc., Diversa Corporation, DNA Sciences, Inc., Elitra Pharmaceuticals Inc., Enchira Biotechnology Corporation, Entropin, Inc., Epoch BioSciences, Inc., Exelixis, Inc., Genaissance Pharmaceuticals, Inc., Gene Logic Inc., Generex Biotechnology Corporation, Genetix Group PLC, Genome Therapeutics Corp., Genometrix Incorporated, Genomic Solutions Inc., Genomica Corporation, Genset, S.A., GenStar Therapeutics Corporation, GPC Biotech AG, GSC, Harvard Bioscience, Inc., Hyseq, Inc., Illumina, Inc., Incyte Genomics, Inc., Infigen, Inc., InterMune, Inc., Invitrogen Corporation, The Jackson Laboratory, Janssen Pharmaceutica &Research Foundation, Keryx Biopharmaceuticals, Inc., Kosan Biosciences Incorporated, Large Scale Biology Corporation, Lexicon Genetics Incorporated, LION bioscience AG, Lynx Therapeutics, Inc., MediChem Life Sciences, Inc., Molecular Devices Corporation, Molecular Dynamics, Inc., Molecular Staging, Inc., MWG Biotech AG, National Institutes of Health, NetGenics, Inc., Orchid BioSciences, Inc., Orion Corporation, Oxford Gene Technology Ltd., Oxford GlycoSciences Plc, Paradigm Genetics, Inc., Perbio Science AB, Pharmagene plc, Pharming Group NV, Pharsight Corporation, Physiome Sciences, Inc., Progen Industries Limited, Ribapharm Inc., Rigel Pharmaceuticals, Inc., Rosetta Inpharmatics, Inc., Roxane Laboratories, Inc., Sangamo BioSciences, Inc., Sequenom, Inc., Signal Research Division, SNP Consortium, Ltd., Stratagene Holding Corporation, Structural Bioinformatics Inc., Synthetech, Inc., Tanox, Inc., TECHNE Corporation, THERMOGENESIS CORP., Third Wave Technologies, Inc., Transgenomic, Inc., Tripos, Inc., Variagenics, Inc., Vasogen Inc., Versicor Inc., Visible Genetics Inc., The Wellcome Trust, Xenogen Corporation, Xenometrix, Inc.

Associated Industries: Drugs - Biotechnology - Research

Keywords: biotechnology, research, drugs, biotech

For a complete index of this report click on http://www.researchandmarkets.com/reports/2949" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/2949

Get two great resources at a value. First, receive a quick but informative guide to the U.S.Biotechnology - Research industry. Learn about industry firm count and employment, geographical areas of growth, SIC and NAICS codes comprising the industry, and see a list of major companies in the industry. Second, get full profile information on 100 major manufacturing firms in the industry. Full profiles include detailed contact information (phone and fax numbers, addresses, etc..) company information fields, (headquarters, ownership, year established, foreign trade, stock ticker) decision makers, SIC and NAICS codes and more. This file contains the Industry Report and Major 100 Manufacturers in PDF format, as well as the Major 100 Manufacturers in a CSV (comma delimited) table for use in spreadsheet programs, or for downloading into databases and contact management systems. Use reports and profiles for prospecting leads, target marketing or market research. All information provided by Harris InfoSource, the leading compiler of information on the manufacturing and technology sectors.

Report Pricing:

Electronic EUR 43 (US$ 40).

ORDERING INFORMATION - FIVE EASY WAYS TO PLACE YOUR ORDER:

ORDER ONLINE: To order this report please click on http://www.researchandmarkets.com/reports/2949" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/2949 ORDER VIA EMAIL: mailto:[e-mail] ORDER VIA FAX-BACK FORM: Click on http://www.researchandmarkets.com/reports/2949" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/2949 Fax to [phone] ORDER VIA POST: Click on http://www.researchandmarkets.com/reports/2949" target="_blank" rel="nofollow ugc noopener">http://www.researchandmarkets.com/reports/2949 Mail to Research and Markets Ltd., Guinness Centre, Taylors Lane, Dublin 8, Ireland ORDER VIA PHONE: Telephone: [phone]

About Research and Markets Ltd.

Research and Markets Ltd. are Europe`s largest resource for market research. R&M distribute thousands of major research publications from the world`s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or [e-mail]

CONTACT: Holly Swift, Public Relations Manager, Research, Research and Markets Ltd. e-mail: [e-mail]

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].

(C)1994-2003 M2 COMMUNICATIONS LTD

JS200

[js200]

Agrinomics Identifies New Genetic Mechanisms That Control Plant Resistance To Fungal Infection
via CDS

January 30, 2003

Agrinomics LLC, a Joint Venture between Exelixis Plant Sciences And Bayer CropScience AG, pioneers plant trait discoveries



PORTLAND, Ore., Jan. 30 /PRNewswire-FirstCall/ -- Scientists at Exelixis Plant Sciences, through its Agrinomics LLC joint venture with Bayer CropScience AG, have identified several new genes that confer resistance to fungal pathogens. This research has provided novel insights that will allow the development of technologies for improved plant productivity.

`These new gene discoveries provide approaches for the direct engineering of fungal resistance in crop plants, as well as important tools for crop breeding,`said Georges Freyssinet, a Member of the Agrinomics Board of Managers and Scientific Advisor at Bayer CropScience AG. `Clearly, there is a need for new mechanisms of providing resistance to fungal pathogens, including the development of new crop varieties.`

`While there is further research involved in bringing our discoveries to crop plants, these exciting discoveries are among our first to reveal novel mechanisms for controlling major diseases of important crops,`added Ry Wagner, chief scientific officer, Agrinomics, and vice president, research, Exelixis Plant Sciences.

Agrinomics, LLC has used the rapid screening and analysis of its Arabidopsis thaliana ACTTAG(TM) collection for commercially valuable traits. ACTTAG(TM) is a positive selection platform that supports high throughput discovery of genes controlling plant traits. One project has targeted the identification of novel dominant genetic mechanisms by which plants resist infection by fungal pathogens. Fungal pathogens impose greater costs upon food growers than any other plant diseases like bacterial or viral diseases. The global fungicide market was more than US $6.0 billion in 2001.



About Agrinomics LLC

Agrinomics, LLC, formed in 1999, conducts research, development and commercialization programs in the field of agricultural functional genomics. The company is a joint venture between Exelixis Plant Sciences -- a wholly owned subsidiary of Exelixis, Inc. (Nasdaq: EXEL) -- and Bayer CropScience A G, has as its mission to identify, develop and commercialize novel traits using the Arabidopsis ACTTAG(TM) Gene Discovery Program. Agrinomics recently entered into an agreement with Renessen LLC to develop seeds with higher oil content in corn and other crops based on traits identified under the ACTTAG Gene Discovery Program.



The forward looking statements contained in this press release involve risks and uncertainties that may affect our research and development efforts and the commercial value of those efforts, in particular whether we will be able to identify or exploit any genes of commercial value from these research efforts. These and other risks are more fully discussed in the `Risk Factors`section of our filing with the U.S. Securities and Exchange Commission.

JS200

[js200]

01/30/2003 (06:01 ET) Agrinomics Identifies New Genetic Mechanisms That Control Plant Resistance To Fungal Infection - PR Newswire
01/29/2003 (06:30 ET) S-8: EXEL Registers 4.8M Shares for Stock Plans - Knobias
01/28/2003 (16:04 ET) New S-8 just released for EXEL - Edgar
01/27/2003 (08:32 ET) RATING(=): Bear Stearns Reiterations, 01/27/2003 - Knobias
01/23/2003 (17:17 ET) VOLUME(+): EXEL Volume 87% > 20-adsv, Stock +0.40% - Knobias


JS200

[js200]

company news

--------------------------------------------------------------------------------

EXEL - Exelixis Incorporated (NASDAQ NM : EXEL)

--------------------------------------------------------------------------------
Exelixis Announces Presentation of Preliminary Phase 2 Data on Rebeccamycin Analogue in Hepatobiliary Tumors

Results Suggest Tolerability and Antitumor Effect in Bile Duct Tumors

MONDAY , FEBRUARY 03, 2003 06:00 AM

SOUTH SAN FRANCISCO, Calif., Feb 3, 2003 /PRNewswire-FirstCall via COMTEX/ -- Preliminary Phase 2 data on the safety and response of the Exelixis, Inc. (Nasdaq: EXEL) anticancer compound, DEAE-rebeccamycin, were presented today at the Fourteenth International Congress on Anti-Cancer Treatment in Paris. Results from 20 patients in this study sponsored by the U.S. National Cancer Institute (NCI) suggest that this rebeccamycin analogue may be safely administered and may result in tumor shrinkage in patients with bile duct tumors. Exelixis and the NCI are collaborating on the development of the rebeccamycin analogue under a Clinical Trials Agreement (CTA).

In a presentation entitled, "Preliminary Toxicity Results of a Multi- institutional Phase II Trial of Rebeccamycin Analogue (RA) in Advanced Hepatobiliary Cancers," Dr. James Posey of the University of Alabama at Birmingham described the results from one cohort of 20 patients with advanced unresectable bile duct cancers (gallbladder cancers and cholangiocarcinomas) who were treated with the rebeccamycin analogue at a dose of 165 milligrams per meter squared per day for five days every three weeks. Of these 20 patients, nine are still alive with median follow-up of 12.5 months. The adverse event profile was manageable and consistent with that previously observed in Phase 1 studies and included transient and reversible myelosuppression, primarily neutropenia. Preliminary results include two partial responses, and 7 patients with stable disease, representing a combined 45% non-progression rate. At the time of this presentation, the Phase 2 trial is ongoing, and additional patients are being enrolled.

"In a disease for which there is no standard therapy, the activity observed in this trial is encouraging for further development of the rebeccamycin analogue," said Dr. Posey. "The side effect profile is acceptable and consistent with other cytotoxic agents."

Exelixis has worldwide rights to the rebeccamycin analogue (internal nomenclature is XL 119), which it received as part of a broad cancer research collaboration established with Bristol-Myers Squibb in July 2001. Phase 2 trials in a broad range of tumors have been conducted by the NCI under the CTA. Pending the outcome of upcoming discussions with the U.S. Food & Drug Administration, Exelixis intends to initiate pivotal trials in collaboration with the NCI of the rebeccamycin analogue in patients with bile duct tumors, anticipated to begin mid-2003. Exelixis market research estimates that the annual incidence of bile duct tumors is approximately 7,500-10,000 cases in the U.S. and in Europe, and a comparable number in Japan and other Asian countries.

Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics, with a focus in the area of oncology. The company is leveraging its fully integrated gene- to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, and Protein Design Labs. The company has also established agricultural research collaborations with Bayer CropScience, Dow Agrosciences and Renessen. Other partners include Merck, Schering-Plough Research Institute, Cytokinetics, Elan and Scios. For more information, please visit the company`s web site at www.exelixis.com.

The forward looking statements contained in this press release involve risks and uncertainties that may affect our research and development efforts, as more fully discussed in the "Risk Factors" section of our 2002 Annual Report on Form 10-K filing with the U.S. Securities and Exchange Commission, and other SEC reports. These risks and uncertainties include, but are not limited to, the preliminary nature of the results from the Phase 2 study described above; the ability of the Company to meet with the FDA in a timely fashion and obtain appropriate guidance to initiate pivotal trials, or any trials, by mid-2003; whether or not the rebeccamycin analogue will continue to show the same or similar adverse events profile and response rate in a larger clinical trial program; and the ability of the Company to successfully show a therapeutic benefit.



NOTE: Exelixis and the Exelixis logo are registered U.S. trademarks.


SOURCE Exelixis, Inc.


CONTACT: Jane M. Green, Ph.D., VP, Corporate Communications of Exelixis,
Inc., [phone], or [e-mail]

URL: http://www.exelixis.com
http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved.


-0-


KEYWORD: California
France
INDUSTRY KEYWORD: BIO
MTC
HEA
SUBJECT CODE: TDS


STOCK SYMBOLS: [(exel)]


JS200

[js200]

Exelixis Provides Update on Cancer Antibody Research Collaboration With Protein Design Labs
via COMTEX

February 25, 2003

SOUTH SAN FRANCISCO, Calif., Feb 25, 2003 /PRNewswire-FirstCall via COMTEX/ --

Exelixis, Inc. (Nasdaq: EXEL) today announced that the research phase of its cancer antibody research agreement with Protein Design Labs, Inc. (Nasdaq: PDLI) will be successfully completed on schedule in June 2003, based on the delivery by Exelixis of a substantial number of antibody targets for cancer drug discovery. PDL will continue to develop antibodies against selected validated targets delivered to them by Exelixis with the goal of initiating clinical development programs. Exelixis retains the right to co-fund development of antibodies against targets selected by PDL and will also regain full rights to certain cancer targets that are not selected for further development by PDL. The companies`research collaboration was established in 2001, with a two-year funded research phase, which will conclude in June 2003.

`In two years, Exelixis has delivered a substantial number of antibody targets to PDL, significantly enriching PDL`s research pipeline. Now, both companies can focus on next steps in what has been a highly productive and collaborative partnership, with the goal of turning these targets into promising new cancer therapies,`said George A. Scangos, president and chief executive officer, Exelixis. `PDL has been a good partner and we look forward to working together toward the development of promising antibodies against these targets.`

`Exelixis has been a great discovery partner. They have delivered a large number of cancer targets, identified under very high standards of scientific excellence and collaboration,`said Mark McDade, chief executive officer, PDL. `We are pleased with the progress of the collaboration and are hopeful that interesting preclinical candidates will emerge by the first half of 2004.`

In May 2001, Exelixis and PDL established a two-year agreement to discover and develop humanized antibodies for the diagnosis, prevention and treatment of cancer. The collaboration combined Exelixis`model organism genetics technology for the identification of new cancer drug targets, with PDL`s antibody and clinical development expertise to create and develop new antibody drug products. The scheduled expiration of the agreement will not result in a change to Exelixis`previously provided financial guidance for the year.

Exelixis is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline and Bristol-Myers Squibb. The company has also established agricultural research collaborations with Bayer CropScience, Dow Agrosciences and Renessen. Other partners include Merck, Schering-Plough Research Institute, Cytokinetics, Elan and Scios. For more information, please visit the company`s web site at www.exelixis.com.

The forward-looking statements contained in this press release involve risks and uncertainties that may affect our research and development efforts, as more fully discussed in the `Risk Factors`section of our respective filings with the U.S. Securities and Exchange Commission. These risks and uncertainties include, but are not limited to, the ability of the companies to successfully develop antibodies against selected targets and to move those antibodies successfully into and through clinical development.

NOTE: Exelixis and the Exelixis logo are registered U.S. trademarks. Protein Design Labs is a registered U.S. trademark.

SOURCE Exelixis, Inc.

Jane M. Green, Ph.D., VP, Corporate Communications of Exelixis, Inc., [phone], or [e-mail]

http://www.exelixis.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

Von Gestern

EXEL
ELELIXIX INC
5.840
+0.120 +2.10%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 2/24/2003 (9) days ago, when the stock price was 5.380. Since then the stock gained 8.55% .

Today the stock closed higher with a lower high and an unchanged low. The volume is extremely low. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Short White Candlestick
Harami Pattern

Today a Short White Candlestick formed. There was a limited price change that may represent consolidation.

The last two candlesticks formed a Harami Pattern. This is a neutral pattern which shows that the buying pressure may be diminishing. However, a confirmation, in the form of a gap down or weak close following this pattern is needed, for it to be considered bearish.

Stock Quote
Last 5.840
Previous Close 5.720
Change +0.120
% Change +2.10%
Volume 48,800
Stock Activity
Open 5.730
Day`s High 5.920
Day`s Low 5.720
52 Week High 14.480
52 Week Low 3.020

Stock Price History
3 Month % Change -24.06
6 Month % Change 22.95
12 Month % Change -48.09
Stock Statistics
50 Day Close MA 6.599
200 Day Close MA 5.982
65 Day Volume MA 208,977

JS200

[js200]

02/28/2003 (13:31 ET) VOLUME(+): EXEL Volume 59% > 20-adsv, Stock +5.40% - Knobias
02/27/2003 (11:02 ET) CONF: EXEL To Present At 2003 BIO CEO Conference @ 14:00 ET - Knobias
02/26/2003 (12:30 ET) Research and Markets: Exelixis, Inc.(EXEL) - Quantitative Valuation Report - M2 Communications
02/25/2003 (17:03 ET) Exelixis Provides Update on Cancer Antibody Research Collaboration With Protein Design Labs - PR Newswire
02/19/2003 (16:07 ET) ERN(+): EXEL/Q4 Adj (34c) vs (26c); Beats Q Est; Mixes Guidance - Knobias


JS200

[js200]

03/07/2003 (15:11 ET) New 10-K just released for EXEL - Edgar
02/28/2003 (13:31 ET) VOLUME(+): EXEL Volume 59% > 20-adsv, Stock +5.40% - Knobias
02/27/2003 (11:02 ET) CONF: EXEL To Present At 2003 BIO CEO Conference @ 14:00 ET - Knobias
02/26/2003 (12:30 ET) Research and Markets: Exelixis, Inc.(EXEL) - Quantitative Valuation Report - M2 Communications
02/25/2003 (17:03 ET) Exelixis Provides Update on Cancer Antibody Research Collaboration With Protein Design Labs - PR Newswire


JS200

[js200]

Von Gestern

EXEL
ELELIXIX INC
5.430
-0.180 -3.21%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 2/24/2003 (11) days ago, when the stock price was 5.380. Since then the stock gained 0.93% .

Today the stock closed lower, close to its low (sign of weakness) with a lower high and a lower low. The volume is extremely low. The security price is trending sideways.

Candlestick Analysis

Today’s Candlestick Patterns:
Short Black Candlestick

Today a Short Black Candlestick formed. There was a limited price change that may represent consolidation

Stock Quote
Last 5.430
Previous Close 5.610
Change -0.180
% Change -3.21%
Volume 37,664
Stock Activity
Open 5.480
Day`s High 5.620
Day`s Low 5.410
52 Week High 14.480
52 Week Low 3.020

Stock Price History
3 Month % Change -31.53
6 Month % Change 11.50
12 Month % Change -51.34
Stock Statistics
50 Day Close MA 6.510
200 Day Close MA 5.956
65 Day Volume MA 189,446

JS200

[js200]

03/18/2003 (12:32 ET) CONF: EXEL To Present At SG Cowen Health Care Conference @ 15:30 ET - Knobias
03/18/2003 (10:16 ET) VOLUME(+): EXEL Volume 8% > 20-adsv, Stock +0.48% - Knobias
03/17/2003 (14:56 ET) VOLUME(+): EXEL Volume 61% > 20-adsv, Stock +13.30% - Knobias
03/07/2003 (15:11 ET) New 10-K just released for EXEL - Edgar
02/28/2003 (13:31 ET) VOLUME(+): EXEL Volume 59% > 20-adsv, Stock +5.40% - Knobias

JS200

[js200]

Last Trade: 6.500 Change: 0.260 (+4.167%)
Previous Close: 6.240 Volume: 668,900
Bid: 6.490 Ask: 6.500
Today`s Open: 5.930 # of Trades: 611

JS200

[js200]

Von Gestern

EXEL
ELELIXIX INC
6.800
+0.560 +8.97%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 3/18/2003 (0) days ago, when the stock price was 6.800. Since then the stock gained 0.00% .

Today the stock closed higher, close to its high (sign of strength) with a higher high and a higher low. The volume is extremely high. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 6.800
Previous Close 6.240
Change +0.560
% Change +8.97%
Volume 853,619
Stock Activity
Open 5.950
Day`s High 6.800
Day`s Low 5.900
52 Week High 14.480
52 Week Low 3.020

Stock Price History
3 Month % Change -13.16
6 Month % Change 50.76
12 Month % Change -47.29
Stock Statistics
50 Day Close MA 6.271
200 Day Close MA 5.880
65 Day Volume MA 181,618

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


03/26/2003 (16:16 ET) New 4 just released for EXEL - Edgar



03/25/2003 (14:12 ET) VOLUME(-): EXEL Volume 50% > 20-adsv, Stock -4.00% - Knobias



03/24/2003 (16:31 ET) New 4 just released for EXEL - Edgar



03/24/2003 (16:29 ET) New 4 just released for EXEL - Edgar



03/21/2003 (16:06 ET) VOLUME(+): EXEL Volume 86% > 20-adsv, Stock +2.27% - Knobias



03/21/2003 (12:07 ET) New 4 just released for EXEL - Edgar



03/20/2003 (16:34 ET) New 4 just released for EXEL - Edgar



03/20/2003 (15:20 ET) New 4 just released for EXEL - Edgar



03/20/2003 (14:57 ET) New 4 just released for EXEL - Edgar



03/19/2003 (16:06 ET) New 4 just released for EXEL - Edgar



03/18/2003 (13:32 ET) CONF: EXEL To Present At SG Cowen Health Care Conference @ 16:30 ET - Knobias



03/18/2003 (12:32 ET) CONF: EXEL To Present At SG Cowen Health Care Conference @ 15:30 ET - Knobias



03/18/2003 (10:16 ET) VOLUME(+): EXEL Volume 8% > 20-adsv, Stock +0.48% - Knobias



03/17/2003 (14:56 ET) VOLUME(+): EXEL Volume 61% > 20-adsv, Stock +13.30% - Knobias



03/07/2003 (15:11 ET) New 10-K just released for EXEL - Edgar

JS200

[js200]

Exelixis Files IND for First Proprietary Anticancer Compound
via COMTEX

March 31, 2003

SOUTH SAN FRANCISCO, Calif., Mar 31, 2003 /PRNewswire-FirstCall via Comtex/ --

Exelixis, Inc. (Nasdaq: EXEL) has submitted its first investigational new drug (IND) application to the U.S. Food &Drug Administration for its proprietary small molecule anticancer compound XL784. The target against which XL784 is directed is a cell surface protease involved in cleavage of growth factors that promote cell growth and differentiation. The target was originally discovered in Exelixis`anti-angiogenesis research program, and shows both anti-angiogenic and anti-proliferative effects. In preclinical studies, XL784 is orally bioavailable, and has shown good potency, pharmacologic activity, and a safety profile appropriate to support Phase 1 studies. The company`s clinical plans include initiating Phase 1 first-in-man studies, to be conducted in healthy volunteers, while continuing to explore the therapeutic utility of the compound in various animal models of disease, including cardiovascular disease.

`Filing the IND for XL784 is a significant achievement for our company, and the credit for this success goes to the dedicated people in our development group and throughout our R&D organization,`said George A. Scangos, Ph.D., president and chief executive officer. `The filing of the IND is the beginning of a development process that we intend to manage prudently. We will learn more about the safety, pharmacokinetic and pharmacodynamic merits of this experimental anticancer compound in Phase I studies and, in parallel, continue to explore other indications in which the compound may have therapeutic application. XL784 is among the first generation of interesting, novel targeted therapies that are emerging from our discovery platform. Our goal is to build a substantial pharmaceutical portfolio by advancing additional promising preclinical programs, filing a series of INDs, and fueling the growth of a diverse clinical pipeline.`

Pending FDA clearance of the IND, Exelixis intends to initiate the Phase 1 program by the late spring 2003. The trial will be conducted at a single center and is designed as a dose escalation study to measure the safety, pharmacokinetics, and biological activity of XL784 following oral administration. Based on preclinical studies, the compound appears appropriate for testing in healthy volunteers and, to date, has shown none of the toxicities associated with traditional anticancer compounds that act through a cytotoxic mechanism. A third-party manufacturer is supplying the drug product to be used in the clinical trial.

Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, and Protein Design Labs. The company has also established agricultural research collaborations with Bayer CropScience, Dow Agrosciences and Renessen. Other partners include Merck, Schering-Plough Research Institute, Cytokinetics, Elan and Scios. For more information, please visit the company`s web site at www.exelixis.com.

The forward looking statements contained in this press release involve risks and uncertainties that may affect our research and development efforts, as more fully discussed in the `Risk Factors`section of our filing with the U.S. Securities and Exchange Commission. These risks and uncertainties include, but are not limited to, the ability of the Company to initiate the Phase 1 clinical study in a rapid and timely manner consistent with a late spring 2003 timeline; the ability of the Company to demonstrate the safety and efficacy of XL784; the commercial value of XL784; and the ability of the Company to successfully develop XL784.

Exelixis and the Exelixis logo are registered U.S. trademarks.

SOURCE Exelixis, Inc.

Jane M. Green, Ph.D., VP, Corporate Communications, of Exelixis, Inc., [phone] or [e-mail]

http://www.prnewswire.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[JS222]

03/31/2003 (08:48 ET) PREMARKET: EXEL Submits IND App To FDA for XL784 - Knobias
03/31/2003 (06:02 ET) Exelixis Files IND for First Proprietary Anticancer Compound - PR Newswire
03/31/2003 (06:00 ET) Exelixis Files IND for First Proprietary Anticancer Compound - PR Newswire
03/26/2003 (16:16 ET) New 4 just released for EXEL - Edgar
03/25/2003 (14:12 ET) VOLUME(-): EXEL Volume 50% > 20-adsv, Stock -4.00% - Knobias

JS200

[JS222]

Von Gestern

EXEL
ELELIXIX INC
7.540
+0.420 +5.90%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 4/1/2003 (9) days ago, when the stock price was 6.721. Since then the stock gained 12.19% .

Today the stock closed higher, at its high (sign of strength) with a lower high and a higher low (sign of decrease in volatility). The volume is low. The security price is trending up.

Candlestick Analysis

Today’s Candlestick Patterns:
Long White Candlestick

Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!

Stock Quote
Last 7.540
Previous Close 7.120
Change +0.420
% Change +5.90%
Volume 97,488
Stock Activity
Open 7.119
Day`s High 7.540
Day`s Low 7.010
52 Week High 11.890
52 Week Low 3.020

Stock Price History
3 Month % Change -1.69
6 Month % Change 139.37
12 Month % Change -36.59
Stock Statistics
50 Day Close MA 6.071
200 Day Close MA 5.898
65 Day Volume MA 186,222

JS200

[js200]

Exelixis Announces First Quarter 2003 Financial Results and Outlook Conference Call and Webcast
via COMTEX

April 23, 2003

SAN FRANCISCO, Apr 23, 2003 /PRNewswire-FirstCall via COMTEX/ --

What: Wednesday, May 7, 2003 @ 2 PM Pacific Time (5 PM Eastern Time) Where: www.exelixis.com/ir How: Visit the Webcast link at the Company`s website at www.exelixis.com/ir to listen to the live broadcast on the day of the event. An archive will also be available at www.exelixis.com/ir until May 21, 2003. Contact: Jane Green Vice President, Corporate Communications 650-837-7579 [e-mail]
Exelixis, Inc. (Nasdaq: EXEL) is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics, with a focus in the area of oncology. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, and Protein Design Labs. The company has also established agricultural research collaborations with Bayer CropScience, Dow Agrosciences and Renessen. Other partners include Merck, Schering-Plough Research Institute, Cytokinetics, Elan and Scios. For more information, please visit the company`s web site at www.exelixis.com.

SOURCE Exelixis, Inc.

Jane Green, Vice President, Corporate Communications of Exelixis, Inc., [phone], or [e-mail]

http://www.exelixis.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

Last Trade: 8.401 Change: 0.151 (+1.830%)
Previous Close: 8.250 Volume: 206,100
Bid: 8.400 Ask: 8.430
Today`s Open: 8.250 # of Trades: 381

JS200

[js200]

http://www.investtech.com/nasdaq/ana/exel.htm

JS200

[js200]

05/05/2003 (16:11 ET) VOLUME(+): EXEL Volume 135% > 20-adsv, Stock +7.43% - Knobias
05/05/2003 (12:09 ET) ERN(-): EXEL/Q1 Adj (48c) vs (43c); Misses Q Est; No Guidance - Knobias
05/05/2003 (08:32 ET) CONF: EXEL To Present At Therapeutic Insight Conference @ 11:30 ET - Knobias
05/05/2003 (08:03 ET) New 10-Q just released for EXEL - Edgar
05/05/2003 (07:00 ET) TABLE: Confirmed Earnings Expected Wednesday, May 7 - Knobias

JS200

[js200]

http://www.knobias.com/news.htm?ticker=EXEL&eid=3.1.c69c3bf1…

JS200

[js200]

VOLUME(+): EXEL Volume 135% > 20-adsv, Stock +7.43%

Monday , May 05, 2003 16:11 ET

This is the 2nd VOLUME alert for EXEL in the past 7 calendar days.

Trading for Exelixis Incorporated (NASDAQ NM: EXEL) has been heavier than usual in today`s session. By 16:10 ET, the stock had already traded 492,000 shares via 1,155 trades. The cumulative volume is 134.57% above its 20-day average of 209,748. Normally the stock experiences around 499 individual trades per session.

So far, today`s volume surge has caused a net rise in EXEL`s stock price. At the time of this alert, the stock was trading at $9.250, up $0.640 (+7.43%).

One year ago, the Company`s shares closed at $8.910. The price has gained more than 3 percent since then.

Over the last 10 trading session EXEL has traded in a range between $7.250 and $8.750 and is currently trading 1.70% below its 52-week high of $9.410 set on November 29, 2002 and 213.56% above its 52-week low of $2.950 from October 09, 2002.

In the previous 3 sessions, EXEL trading has displayed a mixed trend. Closing results have been as follows:

May 02, 2003 --- closed at $8.610 even for the day on 287,300 shares
May 01, 2003 --- closed at $8.610 up $0.091 (+1.07%) on 295,200 shares
April 30, 2003 --- closed at $8.519 up $0.269 (+3.26%) on 304,200 shares

The Company last released news on April 23, 2003:

"Exelixis Announces First Quarter 2003 Financial Results and Outlook Conference Call and Webcast"

EXELIXIS INCORPORATED
Exelixis, Inc. is a biotechnology company whose primary mission is to develop proprietary human therapeutics by leveraging it`s integrated discovery platform to increase the speed, efficiency and quality of pharmaceutical product discovery and development. The Company uses comparative genomics and model system genetics to find new drug targets that it believes would be difficult or impossible to uncover using other experimental approaches. The Company`s research is designed to identify novel genes and proteins expressed by those genes that, when changed, either decrease or increase the activity in a specific disease pathway in a therapeutically relevant manner. These genes and proteins represent either potential product targets or drugs that may treat disease or prevent disease initiation or progression. The Company`s most advanced proprietary pharmaceutical program focuses on drug discovery and development of small molecules in cancer.

JS200

[js200]

Exelixis Announces Departure of Chief Financial Officer
via COMTEX

May 6, 2003

SOUTH SAN FRANCISCO, Calif., May 6, 2003 /PRNewswire-FirstCall via COMTEX/ --

Exelixis, Inc. (Nasdaq: EXEL) announced that Glen Y. Sato, senior vice president, chief financial officer and general counsel, is leaving the company to assume the position of chief financial officer at Protein Design Labs. Mr. Sato`s resignation as an officer and transition from his role at Exelixis will be effective in early June 2003. Prior to joining Exelixis three years ago, Mr. Sato served at PDL for six years, most recently as PDL`s vice president, legal and general counsel. Exelixis is in the process of aggressively recruiting a seasoned financial executive with significant operating and commercial experience to assume the position of chief financial officer, and anticipates announcing this appointment in the near term.

`Glen has made a real contribution to Exelixis`evolution into a product-focused company through his prudent judgment and legal counsel, as well as his integrity and skill in the financial management of our company,` said George A. Scangos, Ph.D., president and chief executive officer. `We respect and support Glen`s decision to return to his former company and to be part of its next stage of growth and development, and the management team and board of directors of Exelixis join me in wishing him well in his future career pursuits. We anticipate effecting a very smooth transition over the next few weeks and will look forward to announcing a new chief financial officer for our team very shortly.`

Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, and Protein Design Labs. The company has also established agricultural research collaborations with Bayer CropScience, Dow Agrosciences and Renessen. Other partners include Merck, Schering-Plough Research Institute, Cytokinetics, Elan and Scios. For more information, please visit the company`s web site at www.exelixis.com.

The forward-looking statements contained in this press release involve risks and uncertainties that may affect our research and development efforts, as more fully discussed in the `Risk Factors`section of our filing with the U.S. Securities and Exchange Commission. These risks and uncertainties include, but are not limited to, the timing of recruitment and hiring of a new chief financial officer.

NOTE: Exelixis and the Exelixis logo are registered U.S. trademarks.

SOURCE Exelixis, Inc.

Jane M. Green, Ph.D., VP, Corporate Communications of Exelixis, Inc., [phone], or [e-mail]

http://www.exelixis.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

EXEL
ELELIXIX INC
8.480
-0.740 -8.03%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 4/25/2003 (11) days ago, when the stock price was 7.680. Since then the stock gained 10.42% .

Today the stock closed lower, close to its low (sign of weakness) with a higher high and an unchanged low. The volume is extremely high. The security price is trending up.



Click here to get a full trend analysis of this stock Candlestick Analysis


Today’s Candlestick Patterns:
Long Black Candlestick
Dark Cloud Cover Pattern

Today a Long Black Candlestick formed. Sellers were aggressive and selling pressure was strong. Be careful, this may be a potential turning point!

The last two candlesticks formed a Dark Cloud Cover Pattern. This is a bearish formation that marks a potential change in trend. However, a confirmation, in the form of a gap down or weak close following this pattern is needed.



Stock Quote
Last 8.480
Previous Close 9.220
Change -0.740
% Change -8.03%
Volume 902,231
Stock Activity
Open 9.370
Day`s High 9.410
Day`s Low 8.390
52 Week High 9.220
52 Week Low 3.020


Stock Price History
3 Month % Change 46.97
6 Month % Change 44.46
12 Month % Change -4.83
Stock Statistics
50 Day Close MA 6.834
200 Day Close MA 6.048
65 Day Volume MA 191,382

JS200

[js200]

05/07/2003 (16:06 ET) New 8-K just released for EXEL - Edgar
05/07/2003 (16:00 ET) Exelixis Announces First Quarter 2003 Financial Results - PR Newswire
05/07/2003 (14:02 ET) ERN/CALL: EXEL To Hold Q1 Conf Call @ 17:00 ET Today - Knobias
05/06/2003 (17:10 ET) New 8-K just released for EXEL - Edgar
05/06/2003 (10:36 ET) VOLUME(-): EXEL Volume 25% > 20-adsv, Stock -3.80% - Knobias

JS200

[js200]

05/12/2003 (13:45 ET) New 4 just released for EXEL - Edgar
05/08/2003 (12:29 ET) New DEFA14A just released for EXEL - Edgar
05/07/2003 (16:06 ET) New 8-K just released for EXEL - Edgar
05/07/2003 (16:00 ET) Exelixis Announces First Quarter 2003 Financial Results - PR Newswire
05/07/2003 (14:02 ET) ERN/CALL: EXEL To Hold Q1 Conf Call @ 17:00 ET Today - Knobias


JS200

[js200]

EXEL
ELELIXIX INC
8.070
+0.170 +2.15%


Daily Commentary
HOLD

Our system recommends HOLD as of today. Previous BUY recommendation was made on 5/16/2003 (7) days ago, when the stock price was 7.680. Since then the stock gained 5.08% .

Today the stock closed higher with a higher high and a higher low. The volume is extremely high. The security price is trending sideways.



Click here to get a full trend analysis of this stock Candlestick Analysis


Today’s Candlestick Patterns:
White Candlestick


Today a White Candlestick formed. Buyers were in control but the buying pressure was not very strong.





Stock Quote
Last 8.070
Previous Close 7.900
Change +0.170
% Change +2.15%
Volume 504,018
Stock Activity
Open 7.920
Day`s High 8.140
Day`s Low 7.870
52 Week High 9.220
52 Week Low 3.020


Stock Price History
3 Month % Change 50.00
6 Month % Change 7.60
12 Month % Change -0.98
Stock Statistics
50 Day Close MA 7.412
200 Day Close MA 6.210
65 Day Volume MA 221,489

JS200

[js200]

http://www.investtech.com/nasdaq/ana/exel.htm

JS200

[js200]

Exelixis Announces Phase 2 Data on Rebeccamycin Analogue in Hepatobiliary Tumors Presented at ASCO
via COMTEX

June 2, 2003

SOUTH SAN FRANCISCO, Calif., Jun 02, 2003 /PRNewswire-FirstCall via Comtex/ --

Exelixis, Inc. (Nasdaq: EXEL) announces that safety and activity data presented at the 2003 annual meeting of the American Society of Clinical Oncology (ASCO) from a Phase 2 trial in 33 patients with bile duct tumors (gall bladder tumors and cholangiocarcinomas) treated with the DEAE- rebeccamycin analogue (XL119), showed encouraging results relative to overall survival and progression free survival (alive without progressive disease, i.e., patients with partial response or stable disease). The safety profile was manageable and was consistent with that previously observed in Phase 1 and 2 studies.

Data from the Phase 2 study were presented in a poster entitled, Multicenter phase II and pharmacokinetic study of rebeccamycin analogue (RA) in advanced biliary cancers, by principal investigator Afshin Dowlati, M.D., of Case Western Reserve University and University Hospitals of Cleveland. The Phase 2 study was sponsored by the U.S. National Cancer Institute (NCI). Exelixis and the NCI are collaborating on the development of the DEAE-rebeccamycin analogue under a Clinical Trials Agreement (CTA).

The Phase 2 trial was conducted in previously untreated patients with advanced biliary cancers, measurable disease and normal liver function. Patients were treated with a dose of 165 milligrams per meter squared per day for five days, every three weeks. Key findings of the study were as follows.

-- Of 33 patients, the median survival was 265 days (approximately 8.8 months). -- Of 30 evaluable patients (excluding three patients who were not on study long enough for evaluation), in patients with progressive disease (treated for four or fewer cycles) the median disease progression free survival was 49 days (less than two months) and the median survival was 149 days (approximately five months). -- In patients without progressive disease (partial response or stable disease, treated for more than four cycles), median disease progression free survival was 154 days (approximately five months; p=0.0004 compared to progressive disease patients) and the median survival was approximately 11 months (p=0.008 compared to progressive disease patients).
`We believe that results of the Phase 2 trial of the DEAE-rebeccamycin analogue in patients with hepatobiliary tumors are suggestive of enhanced clinical benefit, with data showing an overall survival rate of close to nine months,`said Dr. Dowlati. `In a disease for which there is no approved standard of care, these results are highly encouraging. We believe that that the DEAE-rebeccamycin analogue deserves further study in larger patient population in a well-controlled, randomized trial in order to fully explore its therapeutic potential.`

In terms of disease stabilization and safety profile, of 30 evaluable patients, half had clinical courses suggestive of clinical benefit with the following observed: improved performance status, decrease in tumor marker (CA 19.9) or tumor shrinkage (radiologic partial responses or stable disease). As previously observed, the most prevalent side effect was myelosuppression, primarily neutropenia, which was reversible when dosing was reduced or delayed.

A poster entitled, Randomized phase II trial of 2 different administration schedules of rebeccamycin analogue (RA) as 2nd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC), was also presented at ASCO, by Dr. Dowlati.

Exelixis has exclusive worldwide rights to XL119, the DEAE-rebeccamycin analogue, which it received as part of a broad cancer research collaboration established with Bristol-Myers Squibb in July 2001. Ongoing Phase 2 trials in a broad range of tumors are being conducted by the NCI under the CTA. Pending the outcome of current discussions with the U.S. Food &Drug Administration, Exelixis intends to initiate a Phase 3 in collaboration with the NCI of the DEAE-rebeccamycin analogue in patients with bile duct tumors, anticipated to begin later in 2003 or early 2004. Exelixis market research estimates that the annual incidence of bile duct tumors is approximately 7,500-10,000 cases in the U.S. and in Europe, and a comparable number in Japan and other Asian countries.

Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, and Protein Design Labs.

The company has also established agricultural research collaborations with Bayer CropScience, Dow Agrosciences and Renessen. Other partners include Merck, Schering-Plough Research Institute, Cytokinetics, Elan and Scios. For more information, please visit the company`s web site at www.exelixis.com.

The forward-looking statements contained in this press release involve risks and uncertainties that may affect our research and development efforts, as more fully discussed in the `Risk Factors`section of our 2002 Annual Report on Form 10-K filing with the U.S. Securities and Exchange Commission, and other SEC reports. These risks and uncertainties include, but are not limited to, the preliminary nature of the results from the Phase 2 study of XL119 described above; the ability of the Company to meet with the FDA in a timely fashion and develop clinical trials sufficient or appropriate to achieve FDA approval, or to initiate planned trials, in the second half of 2003; whether or not XL 119 will show results consistent with or superior to those achieved in the Phase 2 clinical study reported in this press release; whether XL119 will achieve the appropriate clinical endpoints in a larger clinical trial to show safety and efficacy sufficient to achieve approval to market in the FDA and/or Europe; and the ability of the Company to enroll patients in a timely manner and to successfully achieve approval in order to achieve commercial success.

NOTE: Exelixis and the Exelixis logo are registered U.S. trademarks.

SOURCE Exelixis, Inc.

Jane M. Green, Ph.D., VP, Corporate Communications of Exelixis, Inc., [phone], or [e-mail]

http://www.prnewswire.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


06/05/2003 (16:22 ET) CLOSER(+): Last 90 Min, EXEL Jumps +6.85%; Vol +109% - Knobias



06/04/2003 (13:39 ET) New 4 just released for EXEL - Edgar



06/04/2003 (09:35 ET) New 4 just released for EXEL - Edgar



06/03/2003 (15:37 ET) New 4 just released for EXEL - Edgar



06/03/2003 (15:32 ET) New 4 just released for EXEL - Edgar



06/03/2003 (09:43 ET) RATING(-): Bear Stearns Cuts EXEL to Peer Perform from Outperform - Knobias



06/02/2003 (15:52 ET) New 4 just released for EXEL - Edgar



06/02/2003 (14:36 ET) New 4 just released for EXEL - Edgar



06/02/2003 (14:16 ET) New 4 just released for EXEL - Edgar



06/02/2003 (08:46 ET) PREMRKT: EXEL Reports Data From Phase 2 Trial of XL119 - Knobias



06/02/2003 (06:04 ET) Exelixis Announces Phase 2 Data on Rebeccamycin Analogue in Hepatobiliary Tumors Presented at ASCO - PR Newswire



06/02/2003 (06:00 ET) Exelixis Announces Phase 2 Data on Rebeccamycin Analogue in Hepatobiliary Tumors Presented at ASCO - PR Newswire



05/30/2003 (17:12 ET) New 4 just released for EXEL - Edgar



05/30/2003 (16:10 ET) New 4 just released for EXEL - Edgar



05/30/2003 (16:09 ET) New 4 just released for EXEL - Edgar



05/30/2003 (16:06 ET) New 4 just released for EXEL - Edgar



05/30/2003 (14:06 ET) VOLUME(-): EXEL Volume 46% > 20-adsv, Stock -4.94% - Knobias



05/29/2003 (14:58 ET) New 4 just released for EXEL - Edgar



05/29/2003 (14:46 ET) New 4 just released for EXEL - Edgar



05/28/2003 (13:32 ET) EXEL: Short Interest UP 2.2% to 3.5M in May 2003 - Knobias



05/27/2003 (14:13 ET) New 4 just released for EXEL - Edgar



05/23/2003 (17:20 ET) New 4 just released for EXEL - Edgar



05/23/2003 (15:51 ET) New 4 just released for EXEL - Edgar



05/23/2003 (15:08 ET) New 4 just released for EXEL - Edgar



05/23/2003 (14:28 ET) New 4 just released for EXEL - Edgar

JS200

[js200]

http://www.investtech.com/nasdaq/ana/exel.htm

JS200

[js200]

Exelixis Appoints Steven P. James to Head Commercial Operations
via COMTEX

June 10, 2003

SOUTH SAN FRANCISCO, Calif., Jun 10, 2003 /PRNewswire-FirstCall via COMTEX/ --

Exelixis, Inc. (Nasdaq: EXEL) announces that Steven P. James has been appointed senior vice president, commercial operations. In this new position, Mr. James will be responsible for managing and expanding the company`s business development and corporate development activities, and developing a strategy for pre-commercial and commercial operations. He will report directly to George A. Scangos, Ph.D., president and chief executive officer.

Mr. James has over 20 years of biotechnology and pharmaceutical experience. He joins Exelixis from Sunesis Pharmaceuticals, where he served most recently as chief business officer. In addition to building the company`s highly successful business and corporate development program and establishing several large pharmaceutical alliances, Mr. James was responsible early on for developing Sunesis`operating plan, establishing strategic planning and financial management systems, as well as playing a key role in successful private financings and serving as an early member of the board of directors. Prior to Sunesis, Mr. James was vice president, business development at Isis Pharmaceuticals where he was responsible for a broad range of partnering activities and cultivating new strategic opportunities for the company. Mr. James previously held business development, marketing and operational management positions with Landec Corporation, California Biotechnology (Scios Inc.) and Eli Lilly &Company. He holds a Bachelor`s degree in biology/neuroscience from Brown University and a Master`s degree in management, marketing and healthcare management from Northwestern University, Kellogg School of Management.

`Steve joins Exelixis at a very exciting period in our evolution as a product-focused company, and he will be instrumental in expanding our business operations and strategies,`said Dr. Scangos. `Exelixis has successfully implemented an aggressive and creative corporate partnering strategy, and has established several important, broadly enabling collaborations that have accelerated our growth and increased the productivity of our drug discovery and development efforts. As our development pipeline expands and matures, and as we continue to strengthen and focus our pharmaceutical business, Steve`s proven track record in identifying new business opportunities and cultivating and structuring R&D partnerships, combined with his broad operational management and commercial experience, will add to the depth and breadth of our executive team. We welcome him as a colleague.`

Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, and Protein Design Labs. The company has also established agricultural research collaborations with Bayer CropScience, Dow Agrosciences and Renessen. Other partners include Merck, Schering-Plough Research Institute, Cytokinetics, Elan and Scios. For more information, please visit the company`s web site at www.exelixis.com.

NOTE: Exelixis and the Exelixis logo are registered U.S. trademarks.

SOURCE Exelixis, Inc.

Jane M. Green, Ph.D., VP, Corporate Communications of Exelixis, Inc., [phone], or [e-mail]

http://www.exelixis.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


06/10/2003 (06:00 ET) Exelixis Appoints Steven P. James to Head Commercial Operations - PR Newswire



06/09/2003 (16:07 ET) New 4 just released for EXEL - Edgar



06/09/2003 (14:33 ET) New 4 just released for EXEL - Edgar



06/06/2003 (08:02 ET) CONF: EXEL To Present At Needham Biotech Conference @ 11:00 ET - Knobias



06/05/2003 (16:22 ET) CLOSER(+): Last 90 Min, EXEL Jumps +6.85%; Vol +109% - Knobias



06/04/2003 (13:39 ET) New 4 just released for EXEL - Edgar



06/04/2003 (09:35 ET) New 4 just released for EXEL - Edgar



06/03/2003 (15:37 ET) New 4 just released for EXEL - Edgar



06/03/2003 (15:32 ET) New 4 just released for EXEL - Edgar



06/03/2003 (09:43 ET) RATING(-): Bear Stearns Cuts EXEL to Peer Perform from Outperform - Knobias



06/02/2003 (15:52 ET) New 4 just released for EXEL - Edgar



06/02/2003 (14:36 ET) New 4 just released for EXEL - Edgar



06/02/2003 (14:16 ET) New 4 just released for EXEL - Edgar



06/02/2003 (08:46 ET) PREMRKT: EXEL Reports Data From Phase 2 Trial of XL119 - Knobias



06/02/2003 (06:04 ET) Exelixis Announces Phase 2 Data on Rebeccamycin Analogue in Hepatobiliary Tumors Presented at ASCO - PR Newswire



06/02/2003 (06:00 ET) Exelixis Announces Phase 2 Data on Rebeccamycin Analogue in Hepatobiliary Tumors Presented at ASCO - PR Newswire



05/30/2003 (17:12 ET) New 4 just released for EXEL - Edgar



05/30/2003 (16:10 ET) New 4 just released for EXEL - Edgar



05/30/2003 (16:09 ET) New 4 just released for EXEL - Edgar



05/30/2003 (16:06 ET) New 4 just released for EXEL - Edgar



05/30/2003 (14:06 ET) VOLUME(-): EXEL Volume 46% > 20-adsv, Stock -4.94% - Knobias



05/29/2003 (14:58 ET) New 4 just released for EXEL - Edgar



05/29/2003 (14:46 ET) New 4 just released for EXEL - Edgar



05/28/2003 (13:32 ET) EXEL: Short Interest UP 2.2% to 3.5M in May 2003 - Knobias



05/27/2003 (14:13 ET) New 4 just released for EXEL - Edgar


JS200

[js200]

Exelixis Announces Public Offering of Common Stock
via COMTEX

June 12, 2003

SOUTH SAN FRANCISCO, Calif., Jun 12, 2003 /PRNewswire-FirstCall via COMTEX/ --

Exelixis, Inc. (Nasdaq: EXEL) today announced that it plans to sell 10.0 million shares of its common stock pursuant to an effective shelf registration statement previously filed with the Securities and Exchange Commission. The company also intends to grant an option to the underwriters to purchase up to an additional 1.5 million shares of common stock. All of the shares are being sold by Exelixis.

Goldman, Sachs &Co. is the lead and book running manager for this offering. SG Cowen Securities Corporation is the co-manager.

The securities may not be sold nor may offers to buy be accepted prior to the time that the prospectus supplement is final. This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Copies of the preliminary prospectus supplement may be obtained from the Prospectus Departments of Goldman, Sachs &Co. (85 Broad Street, New York, New York 10004, phone [phone], fax [phone]) and SG Cowen Securities Corporation (c/o ADP, 1155 Long Island Avenue, Edgewood, New York, 11717, phone [phone], fax [phone]).

Exelixis is a genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics.

This press release contains `forward-looking`statements. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as `believes,``anticipates,``plans,``expects,``will,``intends` and similar expressions are intended to identify forward-looking statements. Exelixis does not undertake any obligation to update forward-looking statements.

SOURCE Exelixis, Inc.

Jane M. Green, Ph.D., Vice President, Corporate Communications of Exelixis, Inc., [phone]

http://www.exelixis.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

Dharmacon and Exelixis to Develop 600 Gene siRNA Library
via COMTEX

June 12, 2003

LAFAYETTE, Colo., Jun 12, 2003 /PRNewswire via COMTEX/ --

Dharmacon, Inc., the leading global supplier of innovative RNA and RNA-interference (RNAi) research products, today announced an agreement with Exelixis, Inc. (Nasdaq: EXEL), a leading genomics-based drug discovery company, to develop a short interfering RNA (siRNA) library for approximately 600 proprietary and publicly available genes for kinases and other high priority drug discovery targets. The library is being developed using Dharmacon`s proprietary SMARTselection(TM) and SMARTpool(TM) technology platform and manufactured using its 2`-ACE(R) RNA synthesis chemistry. Exelixis and Dharmacon will apply their strong bioinformatics capabilities to develop the siRNA library. Exelixis plans to use the resulting siRNA reagents for high throughput functional genomic studies designed to characterize drug targets and pathways in mammalian model systems, and Dharmacon will offer siRNA research tools for the publicly available genes to its large base of customers.

RNAi is a powerful new tool of biomedical research that uses siRNA segments to turn off, or silence, the expression of specific genes targeted for study and then assesses the impact on a cell or an entire organism. Dharmacon`s technology overcomes difficulties that have been associated with RNAi by using proprietary algorithms to select the best siRNA sequences for each application, eliminating the need for time-consuming and costly trial and error and then pooling candidates for guaranteed gene silencing. Together these proprietary SMARTselection and SMARTpool technologies create potent and specific gene silencing agents that can accelerate critical investigations across a broad range of biomedical and biological research.

`This collaborative effort with a sophisticated drug discovery innovator like Exelixis reinforces the broad utility and outstanding characteristics of our proprietary SMARTselection and SMARTpool technologies for siRNA research,` said William S. Marshall, Ph.D., executive vice president research and production at Dharmacon. `Our state-of-the-art synthetic chemistries and breakthrough SMARTselection and SMARTpool technologies uniquely enable RNAi studies to be conducted efficiently and cost effectively using high throughput approaches. By routinely achieving unparalleled levels of gene silencing with a very high probability of success, we can help accelerate and enhance the drug discovery capabilities of our customers.`

`We believe that Dharmacon`s technology will provide robust and reliable gene silencing in mammalian cells, thereby contributing to many aspects of our drug discovery efforts,`said Greg Plowman, M.D., Ph.D., senior vice president of research at Exelixis. `We look forward to collaborating with Dharmacon on this exciting project.`

Under the terms of the agreement, Dharmacon and Exelixis will collaborate to develop siRNA reagents for the library. Dharmacon retains rights to the siRNA reagents developed under the agreement using publicly available genes. Dharmacon plans to make the siRNA reagents from this public gene library commercially available to other customers as they are developed. The companies expect the siRNA library to be completed during the third quarter of 2003. Financial terms of the agreement were not disclosed.

About Dharmacon

Dharmacon, Inc. is the world`s leading provider of innovative RNA, RNA- interference (RNAi) research products and related technologies to the life sciences industry. Founded in 1995, Dharmacon discovered and commercialized 2`-ACE(R), a novel, highly productive chemical strategy for RNA synthesis. Using its core expertise in chemistry, biology, bioinformatics, and production, Dharmacon has pioneered a custom small interfering RNA (siRNA) design service that employs its proprietary SMARTselection(TM) and SMARTpool(TM) algorithms for maximizing the efficiency of gene silencing, a powerful and increasingly widely used new technology based on siRNA. The company provides the most reliable and highest quality RNA oligonucleotides and other custom RNA modification options that leverage Dharmacon`s proprietary chemistries. Dharmacon also offers amidites, synthesizers, and reagents for in-house synthesis, providing a total solution for RNAi researchers. Dharmacon is based in Lafayette, Colorado. For more information, please visit the company`s web site at www.dharmacon.com .

For further information, please contact: Mike Deines, VP Marketing of Dharmacon, Inc., [phone]; or media, Stephen Gendel of GendeLLindheim BioCom Partners, [phone], for Dharmacon, Inc.

SOURCE Dharmacon, Inc.

Mike Deines, VP Marketing of Dharmacon, Inc., [phone]; or media, Stephen Gendel of GendeLLindheim BioCom Partners, [phone], for Dharmacon, Inc.

http://www.dharmacon.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

CLOSER(-): Last 90 Min, EXEL Drops -2.37%; Vol +67%

Tuesday , June 17, 2003 16:22 ET

During the last 90 minutes of today`s session, shares of Exelixis Incorporated (NasdaqNM: EXEL) demonstrated a strong DOWNWARD close relative to its 13:30 ET statistics. "Strong Closers" are determined by proprietary Knobias calculations performed during the last segment of each trading day.


sym: EXEL @13:30 ET @CLOSE % CHANGE---------- ----------- ----------- ------------PRICE $8.45 $8.25 -2.37%VOLUME 162,400 271,800 +67.36%#TRADES 477 794 +66.46%DAY-HI $8.95 $8.95 N/ADAY-LO $8.34 $8.22 LATE-LO


JS200

[js200]

Exelixis Initiates Phase 1 Safety Trial for XL784
via COMTEX

June 18, 2003

SOUTH SAN FRANCISCO, Calif., Jun 18, 2003 /PRNewswire-FirstCall via COMTEX/ --

Exelixis, Inc. (Nasdaq: EXEL) has initiated the Phase 1 first-in-man safety trial for its proprietary small molecule anticancer compound XL784. The Phase 1 trial will be conducted at a single center and is expected to enroll approximately 70 healthy subjects in a dose-escalating study intended to explore the safety, pharmacokinetic and pharmacodynamic merits of the compound following oral administration. The trial should be completed within a year. Concurrent with the Phase 1 trial, Exelixis plans to explore the therapeutic utility of the compound in various animal models of disease outside of cancer, including renal and cardiovascular disease.

`XL784 is of significant interest to us because of its preclinical safety profile and activity, and its potential utility and commercial value in treating cancer and other diseases,`said George A. Scangos, Ph.D., president and chief executive officer.

The target against which XL784 is directed is a cell surface protease involved in cleavage of growth factors that promote cell growth and differentiation. The target was originally discovered in Exelixis` anti-angiogenesis research program, and shows both anti-angiogenic and anti-proliferative effects. The compound appears appropriate for testing in healthy volunteers and to date has not shown the toxicities associated with traditional anticancer compounds that act through a cytotoxic mechanism. A third-party manufacturer is supplying the drug product to be used in the clinical trial.

Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, and Protein Design Labs. The company has also established agricultural research collaborations with Bayer CropScience, Dow Agrosciences and Renessen. Other partners include Merck, Schering-Plough Research Institute, Cytokinetics, Elan and Scios. For more information, please visit the company`s web site at www.exelixis.com.

This press release contains `forward-looking`statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as `believes,` `anticipates,``plans,``expects,``will,`and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Exelixis to differ materially from those indicated by these forward-looking statements, including, among others, risks related to whether XL784 administered to healthy volunteers will be safely tolerated, whether additional studies will indicate uses other than cancer and the ultimate potential commercial value of XL784, if any, as well as the other risks detailed from time to time in the Company`s SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2002 and its Quarterly Report on Form 10-Q, as amended, for the quarter ended March 31, 2003. Exelixis does not undertake any obligation to update forward-looking statements.

NOTE: Exelixis and the Exelixis logo are registered U.S. trademarks.

SOURCE Exelixis, Inc.

Jane M. Green, Ph.D., VP, Corporate Communications of Exelixis, Inc., [phone], or [e-mail]

http://www.exelixis.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

Exelixis, Inc. Announces Pricing of Common Stock in Public Offering
via COMTEX

June 20, 2003

SOUTH SAN FRANCISCO, Calif., Jun 20, 2003 /PRNewswire-FirstCall via COMTEX/ --

Exelixis, Inc. (Nasdaq: EXEL) today announced it has priced an offering of 10.0 million shares of its common stock at $7.10 per share. Net proceeds to the company are expected to be approximately $66.3 million. All of the shares are being offered by Exelixis under its currently effective shelf registration statement. The underwriters have been granted an option to purchase up to an additional 1.5 million shares of common stock from Exelixis.

Goldman, Sachs &Co. is the lead and book running manager for this offering. SG Cowen Securities Corporation is the co-manager.

This announcement is neither an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.

The shares of common stock may only be offered by means of a prospectus. Copies of the final prospectus supplement and accompanying prospectus may be obtained from the Prospectus Departments of Goldman, Sachs &Co. (85 Broad Street, New York, New York 10004, phone [phone], fax [phone]) and SG Cowen Securities Corporation (c/o ADP, 1155 Long Island Avenue, Edgewood, New York, 11717, phone [phone], fax [phone]).

Exelixis is a genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics.

This press release contains `forward-looking`statements. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as `believes,``anticipates,``plans,``expects,``will,``intends` and similar expressions are intended to identify forward-looking statements. Exelixis does not undertake any obligation to update forward-looking statements.

SOURCE Exelixis, Inc.

Jane M. Green, Ph.D., Vice President, Corporate Communications of Exelixis, Inc., [phone]

http://www.exelixis.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

Vorsicht !!!!!!!! ¨

http://www.investtech.com/nasdaq/ana/exel.htm

JS200

[js200]

Exelixis, Inc. Announces Underwriters`Exercise of Option To Purchase Additional Shares
via COMTEX

July 7, 2003

SOUTH SAN FRANCISCO, Calif., Jul 7, 2003 /PRNewswire-FirstCall via COMTEX/ --

Exelixis, Inc. (Nasdaq: EXEL) today announced that its underwriters have purchased an additional 1,253,048 shares of common stock pursuant to an option granted to such underwriters in connection with the company`s follow-on common stock offering, which priced on June 19, 2003. Including the sale of these additional shares, the offering will total 11,253,048 shares of common stock at $7.10 per share, resulting in net proceeds to the company of approximately $74.7 million.

Goldman, Sachs &Co. was the lead and book running manager for the offering. SG Cowen Securities Corporation was the co-manager.

All of the shares are being offered by Exelixis under its currently effective shelf registration statement. This announcement is neither an offer to sell nor a solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.

Copies of the final prospectus supplement and accompanying prospectus may be obtained from the Prospectus Departments of Goldman, Sachs &Co. (85 Broad Street, New York, New York 10004, phone [phone], fax [phone]) and SG Cowen Securities Corporation (c/o ADP, 1155 Long Island Avenue, Edgewood, New York, 11717, phone [phone], fax [phone]).

Exelixis is a genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics.

This press release contains `forward-looking`statements. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as `believes,``anticipates,``plans,``expects,``will,``intends` and similar expressions are intended to identify forward-looking statements. Exelixis does not undertake any obligation to update forward-looking statements.

SOURCE Exelixis, Inc.

Jane M. Green, Ph.D., VP, Corporate Communications of Exelixis, Inc., [phone], or [e-mail]

http://www.exelixis.com

Copyright (C) 2003 PR Newswire. All rights reserved.


JS200

[js200]

07/08/2003 (11:26 ET) VOLUME(+): EXEL Volume 12% > 20-adsv, Stock +10.81% - Knobias
07/08/2003 (09:37 ET) BIOTECH (BTC): Piper Jaffray Covers Genomics Stks - Knobias
07/08/2003 (08:34 ET) RATING(1): USB Piper Initiates EXEL Rating @ Strong Buy - Knobias
07/07/2003 (14:33 ET) New 4 just released for EXEL - Edgar
07/07/2003 (06:00 ET) Exelixis, Inc. Announces Underwriters` Exercise of Option To Purchase Additional Shares - PR Newswire


JS200

[js200]

RATING(1): USB Piper Initiates EXEL Rating @ Strong Buy

Tuesday , July 08, 2003 08:34 ET

Issuer: Exelixis Incorporated (NasdaqNM: EXEL)
Analyst Firm: U.S. Bancorp Piper Jaffray

Ratings Action: INITIATE
Current Rating: Strong Buy

Target Price Action: INITIATE
Target Price: $12.00

This rating information was reported by Briefing.com.

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


07/08/2003 (11:26 ET) VOLUME(+): EXEL Volume 12% > 20-adsv, Stock +10.81% - Knobias



07/08/2003 (09:37 ET) BIOTECH (BTC): Piper Jaffray Covers Genomics Stks - Knobias



07/08/2003 (08:34 ET) RATING(1): USB Piper Initiates EXEL Rating @ Strong Buy - Knobias



07/07/2003 (14:33 ET) New 4 just released for EXEL - Edgar



07/07/2003 (06:00 ET) Exelixis, Inc. Announces Underwriters` Exercise of Option To Purchase Additional Shares - PR Newswire



07/01/2003 (16:22 ET) CLOSER(+): Last 90 Min, EXEL Jumps +3.60%; Vol +57% - Knobias



06/30/2003 (18:48 ET) VOLUME(-): EXEL Volume 94% > 20-adsv, Stock -3.51% - Knobias



06/25/2003 (10:32 ET) New 4 just released for EXEL - Edgar



06/25/2003 (10:28 ET) New 4 just released for EXEL - Edgar



06/24/2003 (19:17 ET) EXEL: Short Interest DN 4.3% to 3.3M in Jun 2003 - Knobias



06/24/2003 (16:08 ET) New 4 just released for EXEL - Edgar



06/24/2003 (16:06 ET) New 4 just released for EXEL - Edgar



06/24/2003 (16:02 ET) New 4 just released for EXEL - Edgar



06/24/2003 (15:57 ET) New 4 just released for EXEL - Edgar



06/23/2003 (17:33 ET) 8-K: EXEL Files Previous Jun-20 Press Release - Knobias



06/23/2003 (17:18 ET) New 8-K just released for EXEL - Edgar



06/23/2003 (13:06 ET) New 3 just released for EXEL - Edgar



06/20/2003 (11:51 ET) New 4 just released for EXEL - Edgar



06/20/2003 (11:45 ET) New 424B5 just released for EXEL - Edgar



06/20/2003 (10:55 ET) EXEL Prices 10M Share Offering @ $7.10 - Knobias



06/20/2003 (09:56 ET) VOLUME(-): EXEL Volume 10% > 20-adsv, Stock -2.05% - Knobias



06/20/2003 (06:00 ET) Exelixis, Inc. Announces Pricing of Common Stock in Public Offering - PR Newswire



06/19/2003 (14:21 ET) VOLUME(-): EXEL Volume 57% > 20-adsv, Stock -9.32% - Knobias



06/18/2003 (13:18 ET) RATING(=): JMP Sec Reiterates EXEL Rating @ Mkt Perform - Knobias



06/18/2003 (08:53 ET) EXEL Initiates Phase 1 Trial for Anitcancer Compound - Knobias


JS200

[js200]

WEBCAST ALERT: Exelixis Announces Second Quarter 2003 Financial Results And Outlook Conference Call and Webcast
via COMTEX

July 23, 2003

SAN FRANCISCO, Jul 23, 2003 /PRNewswire-FirstCall via COMTEX/ --

What: Wednesday, August 6, 2003 @ 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) Where: www.exelixis.com

How: Visit the Webcast link at the Company`s website at www.exelixis.com to listen to the live broadcast on the day of the event. An archive will also be available at www.exelixis.com until August 20, 2003.

Contact: Jane Green Vice President, Corporate Communications 650-837-7579 [e-mail]

Exelixis, Inc. (Nasdaq: EXEL) is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics, with a focus in the area of oncology. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline and Bristol-Myers Squibb. The company has also established agricultural research collaborations with Bayer CropScience, Dow Agrosciences and Renessen. Other partners include Merck, Schering-Plough Research Institute, Cytokinetics, Elan and Scios. For more information, please visit the company`s web site at www.exelixis.com.

SOURCE Exelixis, Inc.

Jane Green, Vice President, Corporate Communications of Exelixis, Inc., [phone], or [e-mail]

http://www.exelixis.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200

[js200]

07/24/2003 (15:17 ET) EXEL: Short Interest DN 46.5% to 1.8M in Jul 2003 - Knobias
07/24/2003 (10:33 ET) New 4 just released for EXEL - Edgar
07/23/2003 (16:00 ET) WEBCAST ALERT: Exelixis Announces Second Quarter 2003 Financial Results And Outlook Conference Call and Webcast - PR Newswire
07/16/2003 (12:14 ET) New 4 just released for EXEL - Edgar
07/14/2003 (13:59 ET) New 4 just released for EXEL - Edgar

JS200

[js200]

.
http://www.investtech.com/nasdaq/ana/exel.htm

JS200

[js200]

Exelixis Announces Changes to Board of Directors
via COMTEX

July 31, 2003

SOUTH SAN FRANCISCO, Calif., Jul 31, 2003 /PRNewswire-FirstCall via COMTEX/ --

Exelixis, Inc. (Nasdaq: EXEL) announces that Frank McCormick, Ph.D., has joined the company`s Board of Directors. Dr. McCormick has had a long and distinguished career as a cancer researcher, and is a recognized biotechnology industry leader. He is Director of the University of California, San Francisco Comprehensive Cancer Center, and the David A. Wood Professor of Tumor Biology and Cancer Research in the Department of Microbiology and Immunology at UCSF.

Before assuming his current affiliation with UCSF, Dr. McCormick was the founder and chief scientific officer at Onyx Pharmaceuticals. Prior to that, he served as vice president of research at Chiron Corporation, and vice president of research at Cetus Corporation. He also completed post doctoral fellowships with Dr. Alan Smith at the Imperial Cancer Research Fund in London, England, and with Professor Seymour S. Cohen at the State University of New York at Stony Brook. Dr. McCormick received his Bachelor of Science degree in biochemistry from the University of Birmingham, England and his Ph.D in biochemistry from the University of Cambridge, England. Dr. McCormick is on the editorial board of some of the most prestigious international cancer publications and serves as a board member or advisor to multiple cancer research organizations. He has received numerous awards in recognition of his contributions to the field of cancer research, authored more than 200 scientific publications and edited five books, and holds 21 patents.

`Frank is one of the most creative and innovative cancer researchers anywhere. His laboratory has consistently been at the forefront of new and deeper understanding of the molecular changes that contribute to cancer. Importantly, Frank has been able to pragmatically apply his insights to develop new generations of cancer therapeutics. His energy, enthusiasm, and expertise will be valuable assets to Exelixis as we seek to develop our pipeline of clinical compounds and establish our company as a leader in cancer therapeutics,`said George A. Scangos, Ph.D., president and chief executive officer. `Our entire Board of Directors and management team join me in welcoming Frank to Exelixis, and I look forward to working closely with him as we move the company forward.`

Exelixis also announces that Peter Stadler, Ph.D., Managing Director of Artemis Pharmaceuticals GmbH, Germany, has resigned from the Board. Dr. Stadler was a co-founder of Artemis and is a former executive of Bayer AG where he held various positions in the Central Research Department, the Corporate Staff Division, and the Pharmaceuticals Business Group over a period of 20 years. In 2002, Dr. Stadler was elected Chairman of the Board of the German Association of Biotechnology Industries (DIB). In 2003 he was nominated member of the Board of the European Biotechnology Association EUROPABIO in Brussels. He has been one of the most important figures in the German Biotechnology Industry for the last 15 years, and has had a major impact on the development of biotechnology in Germany. Dr. Stadler was an Exelixis Board member since 1998.

`Under Peter`s leadership, Artemis established its reputation as an international center of excellence in vertebrate model biology and expanded its reach into new commercial ventures, paving the way to its emergence as an independent operating entity later this year,`added Dr. Scangos. `The management and Board of Exelixis are deeply appreciative to Peter for the significant contributions he has made to Exelixis`growth and maturation as an international biotechnology company. He has been a thoughtful advisor and valued member of our management team and Board, and we look forward to continuing our long and valuable close association.`

Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline and Bristol-Myers Squibb. The company has also established agricultural research collaborations with Bayer CropScience, Dow Agrosciences and Renessen. Other partners include Merck, Schering-Plough Research Institute, Cytokinetics, Elan and Scios. For more information, please visit the company`s web site at www.exelixis.com.

NOTE: Exelixis and the Exelixis logo are registered U.S. trademarks.

SOURCE Exelixis, Inc.

Jane M. Green, Ph.D., VP, Corporate Communications of Exelixis, Inc., [phone], or [e-mail]

http://www.exelixis.com

Copyright (C) 2003 PR Newswire. All rights reserved.


JS200

[js200]

08/14/2003 (13:24 ET) VOLUME(+): EXEL Volume 42% > 20-adsv, Stock +0.44% - Knobias
08/12/2003 (14:56 ET) VOLUME(+): EXEL Volume 64% > 20-adsv, Stock +3.96% - Knobias
08/08/2003 (15:07 ET) New 4 just released for EXEL - Edgar
08/07/2003 (16:02 ET) VOLUME(-): EXEL Volume 85% > 20-adsv, Stock -6.31% - Knobias
08/06/2003 (16:45 ET) New 10-Q just released for EXEL - Edgar

JS200

[js200]

09/04/2003 (11:51 ET) BTC: JMP Provides Fall Preview of Biotech Industry - Knobias
09/02/2003 (16:23 ET) CLOSER(+): Last 90 Min, EXEL Jumps +2.07%; Vol +152% - Knobias
08/29/2003 (16:43 ET) New 4 just released for EXEL - Edgar
08/29/2003 (09:12 ET) HCR: Jyske Banks Starts Healthcare Sector at Neutral - Knobias
08/26/2003 (16:17 ET) EXEL: Short Interest DN 0.9% to 1.8M in Aug 2003 - Knobias

JS200

[js200]

Exelixis to Webcast Presentation at the Annual UBS Warburg Global Life Sciences Conference

Thursday , September 18, 2003 06:00 ET

SOUTH SAN FRANCISCO, Calif., Sep 18, 2003 /PRNewswire-FirstCall via COMTEX/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that George Scangos, Ph.D. president and chief executive officer, will present at the Annual UBS Warburg Life Sciences Conference at 3:00 p.m. (Eastern Time) on Tuesday, September 23, 2003.

The presentation will be webcast and may be accessed in the Events page under Investor Information on the Exelixis website at http://www.exelixis.com/index.asp?secPage=events" target="_blank" rel="nofollow ugc noopener">http://www.exelixis.com/index.asp?secPage=events .

About Exelixis, Inc.

Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis` development pipeline includes: XL119 which is anticipated to enter a Phase 3 trial as a potential treatment for bile duct tumors; XL784, an anticancer compound currently in a Phase 1 safety study; XL647 and XL999, anticancer compounds that are potential IND candidates; and multiple compounds in preclinical development. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including SmithKlineBeecham Corporation and Bristol-Myers Squibb Company. The company has also established agricultural research collaborations with Bayer CropScience, Dow AgroSciences and Renessen LLC. Other partners include Merck & Co., Inc., Schering-Plough Research Institute, Inc., Cytokinetics, Inc., Elan Pharmaceuticals, Inc. and Scios Inc. For more information, please visit the company`s web site at www.exelixis.com.

SOURCE Exelixis, Inc.


CONTACT: Jane M. Green, Ph.D., VP, Corporate Communications of Exelixis,
Inc., [phone], or [e-mail]

URL: http://www.exelixis.com
http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved.


-0-


KEYWORD: California
INDUSTRY KEYWORD: BIO
MTC
HEA
SUBJECT CODE: CCA
TDS


STOCK SYMBOLS: [(exel)]

JS200

[js200]

Exelixis Announces Third Quarter 2003 Financial Results and Outlook Conference Call Notice
via COMTEX

October 21, 2003

Oct 21, 2003 /PRNewswire via COMTEX/ --

What: Third Quarter 2003 Financial Results and Outlook Conference Call When: November 5, 2003 at 5:00 p.m. Eastern Time Where: Visit the Events page under Investor Information on the Exelixis website at www.exelixis.com/index.asp?secPage=events or www.firstcallevents.com/service/ajwz391612134gf12.html Archived Replay: Replay available through November 10, 2003 by visiting www.exelixis.com/index.asp?secPage=events or www.firstcallevents.com/service/ajwz391612134gf12.html. Contact: Jane M. Green, Ph.D., VP, Corporate Communications, 650-837-7579
Exelixis, Inc. is a leading genomics-based drug discovery company dedicated to the discovery and development of novel therapeutics. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis`development pipeline includes: XL119 which is anticipated to enter a Phase 3 trial as a potential treatment for bile duct tumors; XL784, an anticancer compound currently in a Phase 1 safety study; XL647 and XL999, anticancer compounds that are potential IND candidates; and multiple compounds in preclinical development. Exelixis has established broad corporate alliances with major pharmaceutical and biotechnology companies, including SmithKlineBeecham Corporation and Bristol-Myers Squibb Company. The company has also established agricultural research collaborations with Bayer CropScience, Dow AgroSciences and Renessen LLC. Other partners include Merck &Co., Inc., Schering-Plough Research Institute, Inc., Cytokinetics, Inc., Elan Pharmaceuticals, Inc. and Scios Inc. For more information, please visit the company`s web site at www.exelixis.com.

NOTE: Exelixis and the Exelixis logo are registered U.S. trademarks.

SOURCE Exelixis, Inc.

Jane M. Green, Ph.D., VP, Corporate Communications, [phone]

http://www.exelixis.com

Copyright (C) 2003 PR Newswire. All rights reserved.

JS200